TB Alliance Case Study on Expanding Access to Life-Saving Tuberculosis Treatments Published by INSEAD
MBA students tackle one of global health’s toughest challenges – how to reduce drug rollout timelines to just one year […]
News
Academic Study Finds TB Alliance’s Access Approach Successfully Accelerated Uptake of New TB Treatments
Findings underscore critical role of product development partnerships in delivering both innovation and access GENEVA (April 24, 2026)—A new peer-reviewed
New Report: LIFT-TB Helped Cut Time to Global Uptake of Improved Drug-Resistant TB Treatments from Nearly a Decade to Three Years
Country-led evidence and implementation support enabled faster adoption of shorter, more effective regimens worldwide SEOUL (April 13, 2026)—A new independent
TB Alliance Congratulates Bruce Carter on His Appointment as an Officer of the Order of the British Empire
TB Alliance warmly congratulates Bruce Carter, PhD, on his appointment as an Officer of the Order of the British Empire
Doris Macharia Elected President of TB Alliance’s Global TB Stakeholders, Joins Board of Directors
Global health leader brings deep expertise in advancing children’s health, HIV, and global health equity NEW YORK (March 2, 2026)—TB
TB Alliance Announces New Collaboration with Novartis to Advance the Research and Development of Telacebec for Leprosy
New collaboration aims to advance innovation for a neglected and stigmatizing disease affecting hundreds of thousands worldwide NEW YORK (January
TB Alliance and Lupin Announce Collaboration to Advance and Commercialize Telacebec for Multiple Neglected Diseases
Partnership will support the development of investigational drug telacebec for the treatment of tuberculosis, leprosy, and Buruli ulcer NEW YORK
TB Alliance and Asian Development Bank Forge Strategic Partnership to Strengthen Regional Efforts Against Tuberculosis
New York, USA and Manila, Philippines — [Date] — TB Alliance and the Asian Development Bank (ADB) have announced a
Promising New Data on Pediatric Use of Pretomanid in Children with Drug-Resistant Tuberculosis Presented at 2025 Union Conference
Positive results mark an important step forward in efforts to develop effective treatments for children with drug-resistant TB COPENHAGEN, Denmark
Phase 2 Clinical Trial Results Show Potential to Shorten TB Treatment Time
Thuto Pulane, a TB survivor and participant in the NC-009 trial, at a follow-up appointment with Dr. William Brumskine, NC-009